AUSTIN, Texas--(BUSINESS WIRE)--Apollo Endosurgery, Inc. (“Apollo”) (NASDAQ:APEN), a leader in less invasive medical devices for bariatric and gastrointestinal procedures, today announced financial results for the fourth quarter and year ended December 31, 2016.
Fourth Quarter Highlights
Total revenue of $15.4 million
Endo-bariatric sales of $7.6 million, up 26% year-over-year, including 9% growth in the U.S. and 50% international growth Completed reverse-merger with LPATH, Inc. (“Lpath”), raising $29.0 million; began trading on NASDAQ Global Market
Full Year Highlights
Total revenue of $64.9 million
Endo-bariatric sales of $31.9 million, up 86% year-over-year, including 70% growth in the U.S. and 105% international growth
Trained over 800 U.S. physicians on the ORBERA® Intragastric Balloon since FDA approval in August 2015, establishing #1 market position
Accounts representing more than 200 trained U.S. physicians have re-ordered ORBERA during 2016 following consumption of their initial stocking order
